Abstract
The article examines the dynamics of the Russian budget market for triple fixeddose combinations used in the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA) over the period from 2020 to 2025. It describes the main combinations available on the market. The analysis demonstrates a steady increase in sales volume and gradual growth in the share of new drugs. The study highlights the significance of these medications as universal tools in treating broncho-obstructive syndromes and identifies prospects for further expansion of their employment in clinical practice.